Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

28.85 +0.50 (+1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,372,957
Open 28.37
Bid (Size) 25.45 (5)
Ask (Size) 28.00 (1)
Prev. Close 28.35
Today's Range 28.20 - 29.49
52wk Range 21.24 - 33.00
Shares Outstanding 163,426,943
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Treating Bipolar 1 Disorder
SOURCE: Alkermes 
Via 3BL Media
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets

Performance

YTD
+19.46%
+19.46%
1 Month
+1.33%
+1.33%
3 Month
+19.56%
+19.56%
6 Month
+26.09%
+26.09%
1 Year
+33.63%
+33.63%

More News

Read More
Alkermes Awarded 2022 Platinum Bell Seal for Workplace Mental Health
Via 3BL Media
Tips to Improve Mental Well-Being
Via 3BL Media
Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital
Via 3BL Media
Recap: Alkermes Q1 Earnings
Via Benzinga
Expert Ratings for Alkermes
Via Benzinga
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
Via 3BL Media
Looking Into Alkermes's Return On Capital Employed
Via Benzinga
61 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
LGBTQ+ People Are More Likely to Experience a Mental Health Condition
Via 3BL Media
Topics LGBTQ
Exposures Diversity
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
Via Benzinga
Alkermes's Earnings Outlook
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022
Via Benzinga
Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen
Via Benzinga
This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Via Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
Via Benzinga
Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops
Via Investor's Business Daily
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Via Benzinga
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Via FinancialNewsMedia
Topics Economy
Exposures Economy
The Ruble Is Rubble
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.